KYAN Technologies Pte. Ltd. (“KYAN”), a biotech company that has developed clinically utilized functional precision medicine technology, today announced a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, December 7-10, 2024. The presentation will highlight the ability of KYAN’s Optim.AI™ platform (also known as “QPOP”) to evaluate immunotherapy drugs in combination.
Optim.AI™ has already been applied across multiple cancers to predict responses to targeted therapies and chemotherapies, with high accuracy. The demonstrated feasibility of Optim.AI™ in evaluating immunotherapies is an exciting and pivotal step forward as the introduction of more and more immunotherapies, especially as many are given in combination, significantly complicates choosing effective treatment.
Details related to the poster presentations are as follows:
Title: A Combinatorial Functional Precision Medicine Platform to Evaluate Immunotherapy-Based Combinations in Non-Hodkin Lymphoma
Number: 1416
Presenter: Edward Chow
Program: Oral and Poster Abstracts
Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
Time and Location:
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)